ArticleBiomedicines2022
Natural Compounds Such as
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Ecotoxicological Insights From Ex Vivo Exposure of Whole Blood to PFOS and Glyphosate: Oxidative Stress and Immune Disruption.Environmental toxicology · 2026Article
- Nrf2-Activating Natural Compounds in Neurodegenerative Diseases: Targeting Oxidative Stress and Protein Aggregation.International journal of molecular sciences · 2026Review
- Characterization of Children with Intellectual Disabilities and Relevance of MushroomNutrients · 2026Article
- Utilizing amicroPublication biology · 2026Article
- Neuroprotective Effects of Mushroom Biomass Digestive Fractions and Gut Microbiota Metabolites in Microglial andNutrients · 2025Article
- Functional Foods Alleviate Behavioral Alterations and Improve GABAergic System Regulating TLR-4/NF-κB Axis in Valproic-Induced Autism.Brain and behavior · 2025Article
- Supporting Neurologic Health with Mushroom Nutrition.Nutrients · 2025Review
- Hormetic Nutrition and Redox Regulation in Gut-Brain Axis Disorders.Antioxidants (Basel, Switzerland) · 2024Review
- Role of Natural Compounds Modulating Heme Catabolic Pathway in Gut, Liver, Cardiovascular, and Brain Diseases.Biomolecules · 2024Review
- Frankincense: A neuronutrient to approach Parkinson's disease treatment.Open medicine (Warsaw, Poland) · 2024Review
- Redox Modulation of Meniere Disease byCurrent neuropharmacology · 2024Article
- Modulation of TLR4/NFκB Pathways in Autoimmune Myocarditis.Antioxidants (Basel, Switzerland) · 2023Article
- MemophenolInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundA growing body of research suggests that oxidative stress and neuroinflammation are early pathogenic features of neurodegenerative disorders. In recent years, the vitagene system has emerged as a potential target, as it has been shown to have a high neuroprotective power. Therefore, the discovery of molecules capable of activating this system may represent a new therapeutic target to limit the deleterious consequences induced by oxidative stress and neuroinflammation, such as neurodegeneration. Lipoxins are derived from arachidonic acid, and their role in the resolution of systemic inflammation is well established; however, they have become increasingly involved in the regulation of neuroinflammatory and neurodegenerative processes. Our study aimed at activating the NF-E2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) redox system and increasing lipoxin A4 for the modulation of antioxidant stress and neuroinflammation through the action of two fungi in a rotenone-induced Parkinson's model.
methodsDuring the experiment, mice received
resultsThe results obtained highlighted the ability of these two fungi and, in particular, their ability through their association to act on neuroinflammation through the nuclear factor-kB pathway and on oxidative stress through the Nrf2 pathway. This prevented dopaminergic neurons from undergoing apoptosis and prevented the alteration of typical Parkinson's disease (PD) markers and α-synuclein accumulation. The action of
conclusionsSince these two mushrooms are subject to fewer regulations than traditional drugs, they could represent a promising nutraceutical choice for preventing PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.